JP2013518882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518882A5 JP2013518882A5 JP2012551997A JP2012551997A JP2013518882A5 JP 2013518882 A5 JP2013518882 A5 JP 2013518882A5 JP 2012551997 A JP2012551997 A JP 2012551997A JP 2012551997 A JP2012551997 A JP 2012551997A JP 2013518882 A5 JP2013518882 A5 JP 2013518882A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- medicament
- day
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CN(C1NCN=C2NC=CC12)[C@@](C1)C(*)CCN1C(N*)=O Chemical compound CN(C1NCN=C2NC=CC12)[C@@](C1)C(*)CCN1C(N*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30191510P | 2010-02-05 | 2010-02-05 | |
| US61/301,915 | 2010-02-05 | ||
| PCT/US2011/022216 WO2011097087A1 (en) | 2010-02-05 | 2011-01-24 | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013518882A JP2013518882A (ja) | 2013-05-23 |
| JP2013518882A5 true JP2013518882A5 (enExample) | 2014-03-13 |
Family
ID=43629121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551997A Withdrawn JP2013518882A (ja) | 2010-02-05 | 2011-01-24 | ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120309776A1 (enExample) |
| EP (1) | EP2531508A1 (enExample) |
| JP (1) | JP2013518882A (enExample) |
| CN (1) | CN102822177A (enExample) |
| AU (1) | AU2011213198B2 (enExample) |
| BR (1) | BR112012019511A2 (enExample) |
| CA (1) | CA2788071A1 (enExample) |
| MX (1) | MX2012009074A (enExample) |
| WO (1) | WO2011097087A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103214484B (zh) | 2005-12-13 | 2016-07-06 | 因塞特控股公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
| JP2015528501A (ja) * | 2012-09-12 | 2015-09-28 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 白斑の治療法 |
| TWI761825B (zh) | 2012-11-15 | 2022-04-21 | 美商英塞特控股公司 | 盧梭利替尼之緩釋性劑型 |
| CN103896946B (zh) * | 2012-12-28 | 2018-04-03 | 浙江导明医药科技有限公司 | 用于预防及治疗多种自身免疫疾病的新化合物 |
| US20160123982A1 (en) | 2013-02-04 | 2016-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assaying jak2 activity in red blood cells and uses thereof |
| US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| EP3006445B1 (en) * | 2013-06-07 | 2017-11-15 | Jiangsu Hengrui Medicine Co. Ltd. | Bisulfate of janus kinase (jak) inhibitor and preparation method therefor |
| SG11201600815WA (en) | 2013-08-07 | 2016-03-30 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| CN105732637B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| US10435428B2 (en) | 2015-11-24 | 2019-10-08 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease |
| WO2017143014A1 (en) | 2016-02-16 | 2017-08-24 | Brian Kim | Jak inhibitors and uses thereof |
| WO2018165250A1 (en) | 2017-03-08 | 2018-09-13 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of tofacitinib |
| WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
| EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
| JP2020520955A (ja) | 2017-05-23 | 2020-07-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ヤヌスキナーゼ阻害剤のグルクロニドプロドラッグ |
| EP3609903A1 (en) | 2017-05-23 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Thiocarbamate prodrugs of tofacitinib |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0831829B1 (en) * | 1995-06-07 | 2003-08-20 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| PL198640B1 (pl) | 1998-06-19 | 2008-07-31 | Pfizer Prod Inc | Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków |
| EA006227B1 (ru) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| EA006153B1 (ru) * | 2000-06-26 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ |
| JP2004502665A (ja) * | 2000-06-30 | 2004-01-29 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療する化合物 |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| CN101353321A (zh) | 2002-11-21 | 2009-01-28 | 辉瑞产品公司 | 3-氨基-哌啶衍生物及其制备方法 |
| US7732237B2 (en) | 2005-06-27 | 2010-06-08 | The Regents Of The University Of California | Quantum dot based optoelectronic device and method of making same |
| CN101233138A (zh) * | 2005-07-29 | 2008-07-30 | 辉瑞产品公司 | 吡咯并[2，3-d]嘧啶衍生物、其中间体和合成方法 |
| WO2008029237A2 (en) * | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
-
2011
- 2011-01-24 EP EP11703762A patent/EP2531508A1/en not_active Withdrawn
- 2011-01-24 MX MX2012009074A patent/MX2012009074A/es unknown
- 2011-01-24 US US13/576,685 patent/US20120309776A1/en not_active Abandoned
- 2011-01-24 CN CN2011800171067A patent/CN102822177A/zh active Pending
- 2011-01-24 CA CA2788071A patent/CA2788071A1/en not_active Abandoned
- 2011-01-24 BR BR112012019511A patent/BR112012019511A2/pt not_active IP Right Cessation
- 2011-01-24 AU AU2011213198A patent/AU2011213198B2/en not_active Expired - Fee Related
- 2011-01-24 WO PCT/US2011/022216 patent/WO2011097087A1/en not_active Ceased
- 2011-01-24 JP JP2012551997A patent/JP2013518882A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011215638B2 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
| JP7541594B2 (ja) | ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| KR20130079429A (ko) | 헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법 | |
| KR20120120416A (ko) | Ｍｇｌｕｒ4 알로스테릭 강화제로서 벤즈이속사졸 및 아자벤즈이속사졸, 조성물, 및 신경 기능이상을 치료하는 방법 | |
| JP2013526544A5 (enExample) | ||
| CL2011000353A1 (es) | Compuestos derivados de 1-{4-[metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida o una sal farmaceuticamente aceptable; forma cristalina de la sal maleato; procedimiento de preparacion; composicion farmaceutica; y uso para tratar enfermedades alergicas, cancer, lupus. | |
| JP2013542247A5 (enExample) | ||
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| JP2012514655A (ja) | フッ素含有化合物およびその使用法 | |
| JP2011006480A5 (enExample) | ||
| KR20120115252A (ko) | Ｍｇｌｕｒ4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법 | |
| JP2015509075A5 (enExample) | ||
| CA3093445A1 (en) | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors | |
| JP2013518036A5 (enExample) | ||
| JP2013508382A5 (enExample) | ||
| JP2019529460A5 (enExample) | ||
| JP2016513124A5 (enExample) | ||
| JP2011526286A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| SI2864328T1 (en) | Pharmaceutically active compounds | |
| JP2014515405A (ja) | オピオイド受容体アゴニストの逐次投与のための組成物 | |
| CN105263922B (zh) | 三唑化合物及其作为γ分泌酶调节剂的用途 | |
| MX2010013978A (es) | Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas. | |
| JP2024540590A (ja) | Ｂｃｌ－２阻害剤としての化合物 |